An endocrine clinic stresses that the three drugs people keep hearing about are distinct medications, in a general explainer for patients weighing options.
Recap by typeshit. Post by @the_endocrine_center on Instagram.
A retrospective study in Cureus looks back at how well once-weekly semaglutide worked, and how safe it was, for teenagers with obesity.
Presented at Sleep Europe 2026, both trials found retatrutide lowered the apnea-hypopnea index more than placebo, including in people with type 2 diabetes.
Endpoints News
Endpoints reports Eli Lilly is building a case for its triple agonist beyond obesity, where a launch is expected next year, with sleep apnea next in line.
Observational data link GLP-1 drugs to fewer cases of some cancers, but trials have yet to show they prevent cancer or help survival after a diagnosis.
A free talk on Sat, Oct 17 at 10:30 AM in Lisle, IL on whether weight lost on GLP-1s is fat or muscle, with a vegetarian lunch included.
The review weighs the two FDA-approved MASH drugs, which haven't been tested head to head, and notes some patients may do well on both.
Loading…